Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05035784
Other study ID # A333--1
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date November 10, 2020
Est. completion date May 13, 2022

Study information

Verified date November 2023
Source Shengjing Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Constipation is the most common complaint in childhood gastrointestinal disease, affecting an estimated 20% of the global children.The treatment strategies consist of diet control, behavioral intervention and oral and sometimes rectal laxatives. Given higher success rate and fewer side effects, the laxative PEG3350 has been considered the first choice in childhood constipation.However, effectiveness of PEG 3350 laxative is not lasting, and the use of PEG increases the risk of fecal incontinence. Additional treatment interventions are still necessary.Enema can act directly on the rectum and distal colon to quickly relieve symptoms of fecal impaction which is considered one of main source of intractable constipation. Children with fecal impaction who received enema had fewer fecal incontinence and diarrhea than children who received PEG. There have been lots of evidence that enema is effective in fecal impaction in children with functional constipation.But there are still cases of recurrences noted after enema. Fecal bacteria transplantation (FMT) is a new treatment method emerging in recent years, which is widely used in the treatment of functional gastrointestinal diseases. FMT has been proved to play a very prominent role in correcting intestinal flora disorders. By transplanting exogenous flora into the intestinal tract of patients, FMT can inhibit bacterial reproduction, regulate intestinal environment and cascade the body immunity, so as to achieve the therapeutic effect of disease. Retrograde colonic enema with FMT, an new method, provides the possibility for the treatment of childhood constipation. However, there is still a lack of evidence-based support for the treatment of childhood constipation by retrograde colonic enema with FMT. Therefore, we designed a randomized, controlled, double-blind clinical trial to confirm the efficacy and safety of retrograde colonic enema with FMT in the treatment of childhood constipation.


Recruitment information / eligibility

Status Completed
Enrollment 110
Est. completion date May 13, 2022
Est. primary completion date January 20, 2022
Accepts healthy volunteers Accepts Healthy Volunteers
Gender All
Age group 4 Years to 14 Years
Eligibility Inclusion criteria: - 4-14 years old; - Roman IV criteria for childhood constipation; - After a course of PEG and a course of Chinese medicine treatment was ineffective; - Barium enema showing fecal impaction. Exclusion criteria: - Congenital and/or acquired intestinal diseases, such as congenital megacolon, intestinal stenosis, polyps, Crohn's disease, tuberculosis, inflammation, and tumors; - Anorectal diseases, such as anal atresia, fistula, abscess, and tumor; - Neurological diseases, such as brain and spinal cord diseases; - genetic metabolic diseases; - psychosocial and behavioral diseases; - other systemic diseases; - Refused to participate in.

Study Design


Intervention

Drug:
Fecal supernatant
Fecal supernatant from a child registered in the specimen bank that matches the subject's age, gender, and weight .
Placebo
a placebo designed to match the FMT+RCE group based on appearance including 0.9% physiological saline.

Locations

Country Name City State
China Shengjing Hospital Shenyang Liaoning

Sponsors (1)

Lead Sponsor Collaborator
Shengjing Hospital

Country where clinical trial is conducted

China, 

References & Publications (13)

Clemente MG, Mandato C, Poeta M, Vajro P. Pediatric non-alcoholic fatty liver disease: Recent solutions, unresolved issues, and future research directions. World J Gastroenterol. 2016 Sep 28;22(36):8078-93. doi: 10.3748/wjg.v22.i36.8078. — View Citation

Dai M, Liu Y, Chen W, Buch H, Shan Y, Chang L, Bai Y, Shen C, Zhang X, Huo Y, Huang D, Yang Z, Hu Z, He X, Pan J, Hu L, Pan X, Wu X, Deng B, Li Z, Cui B, Zhang F. Rescue fecal microbiota transplantation for antibiotic-associated diarrhea in critically ill patients. Crit Care. 2019 Oct 21;23(1):324. doi: 10.1186/s13054-019-2604-5. — View Citation

Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis. 2011 Nov;53(10):994-1002. doi: 10.1093/cid/cir632. — View Citation

Gurram B, Sue PK. Fecal microbiota transplantation in children: current concepts. Curr Opin Pediatr. 2019 Oct;31(5):623-629. doi: 10.1097/MOP.0000000000000787. — View Citation

Kassam Z, Dubois N, Ramakrishna B, Ling K, Qazi T, Smith M, Kelly CR, Fischer M, Allegretti JR, Budree S, Panchal P, Kelly CP, Osman M. Donor Screening for Fecal Microbiota Transplantation. N Engl J Med. 2019 Nov 21;381(21):2070-2072. doi: 10.1056/NEJMc1913670. Epub 2019 Oct 30. No abstract available. — View Citation

Ohkusa T, Koido S, Nishikawa Y, Sato N. Gut Microbiota and Chronic Constipation: A Review and Update. Front Med (Lausanne). 2019 Feb 12;6:19. doi: 10.3389/fmed.2019.00019. eCollection 2019. — View Citation

Shen ZH, Zhu CX, Quan YS, Yang ZY, Wu S, Luo WW, Tan B, Wang XY. Relationship between intestinal microbiota and ulcerative colitis: Mechanisms and clinical application of probiotics and fecal microbiota transplantation. World J Gastroenterol. 2018 Jan 7;24(1):5-14. doi: 10.3748/wjg.v24.i1.5. — View Citation

Tian H, Ding C, Gong J, Ge X, McFarland LV, Gu L, Wei Y, Chen Q, Zhu W, Li J, Li N. Treatment of Slow Transit Constipation With Fecal Microbiota Transplantation: A Pilot Study. J Clin Gastroenterol. 2016 Nov/Dec;50(10):865-870. doi: 10.1097/MCG.0000000000000472. — View Citation

Vindigni SM, Surawicz CM. Fecal Microbiota Transplantation. Gastroenterol Clin North Am. 2017 Mar;46(1):171-185. doi: 10.1016/j.gtc.2016.09.012. — View Citation

Vriesman MH, Koppen IJN, Camilleri M, Di Lorenzo C, Benninga MA. Management of functional constipation in children and adults. Nat Rev Gastroenterol Hepatol. 2020 Jan;17(1):21-39. doi: 10.1038/s41575-019-0222-y. Epub 2019 Nov 5. — View Citation

Wang S, Xu M, Wang W, Cao X, Piao M, Khan S, Yan F, Cao H, Wang B. Systematic Review: Adverse Events of Fecal Microbiota Transplantation. PLoS One. 2016 Aug 16;11(8):e0161174. doi: 10.1371/journal.pone.0161174. eCollection 2016. — View Citation

Woodworth MH, Carpentieri C, Sitchenko KL, Kraft CS. Challenges in fecal donor selection and screening for fecal microbiota transplantation: A review. Gut Microbes. 2017 May 4;8(3):225-237. doi: 10.1080/19490976.2017.1286006. Epub 2017 Jan 27. — View Citation

Xu D, Chen VL, Steiner CA, Berinstein JA, Eswaran S, Waljee AK, Higgins PDR, Owyang C. Efficacy of Fecal Microbiota Transplantation in Irritable Bowel Syndrome: A Systematic Review and Meta-Analysis. Am J Gastroenterol. 2019 Jul;114(7):1043-1050. doi: 10.14309/ajg.0000000000000198. — View Citation

* Note: There are 13 references in allClick here to view all references

Outcome

Type Measure Description Time frame Safety issue
Primary improvement of spontaneous bowel movements(SBMs) per week the frequency of defecation without drugs or other auxiliary methods Baseline
Primary improvement of spontaneous bowel movements(SBMs) per week the frequency of defecation without drugs or other auxiliary methods at the end of 4-weeks FMT treatment
Primary improvement of spontaneous bowel movements(SBMs) per week the frequency of defecation without drugs or other auxiliary methods at the end of 12 weeks follow-up
Primary Satisfaction with bowel function Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no). Baseline
Primary Satisfaction with bowel function Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no). at the end of 4-weeks FMT treatment
Primary Satisfaction with bowel function Satisfaction with bowel function was collected from the parents and defined as whether they were satisfied with bowel function after the treatment (yes or no). at the end of 12 weeks follow-up
Secondary Bowel movements the frequency of bowel movements per week Baseline
Secondary Bowel movements the frequency of bowel movements per week at the end of 4-weeks FMT treatment
Secondary Bowel movements the frequency of bowel movements per week at the end of 12 weeks follow-up
Secondary Painful or hard bowel movements The feelings of children during defecation Baseline
Secondary Painful or hard bowel movements The feelings of children during defecation at the end of 4-weeks FMT treatment
Secondary Painful or hard bowel movements The feelings of children during defecation at the end of 12 weeks follow-up
Secondary Large diameter or scybalous stools appearance and wetness of stool Baseline
Secondary Large diameter or scybalous stools appearance and wetness of stool at the end of 4-weeks FMT treatment
Secondary Large diameter or scybalous stools appearance and wetness of stool at the end of 12 weeks follow-up
Secondary Excessive volitional stool retention The number of children who intentionally control or reduce the frequency of defecation Baseline
Secondary Excessive volitional stool retention The number of children who intentionally control or reduce the frequency of defecation at the end of 4-weeks FMT treatment
Secondary Excessive volitional stool retention The number of children who intentionally control or reduce the frequency of defecation at the end of 12 weeks follow-up
Secondary Encopresis the frequency of fecal incontinence Baseline
Secondary Encopresis the frequency of fecal incontinence at the end of 4-weeks FMT treatment
Secondary Encopresis the frequency of fecal incontinence at the end of 12 weeks follow-up
See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04436874 - Fecal Microbiota Transplantation in the Treatment of Inflammatory Bowel Disease N/A
Recruiting NCT03325855 - Fecal Microbiota Transplant National Registry
Completed NCT06162702 - Clinical Study of Fecal Microbiota Transplantation in the Treatment of Small Intestinal Bacterial Overgrowth (SIBO) N/A
Active, not recruiting NCT05607745 - Dietary Counseling Coupled With FMT in the Treatment of Obesity and NAFLD - the DIFTOB Study N/A
Completed NCT05121285 - Distribution of FMT After Delivery by · Lower GI Endoscopy vs Enema With and Without Positioning of the Patient N/A
Active, not recruiting NCT05917379 - The Safety and Efficacy of FMT in Patients With CID Phase 1/Phase 2
Recruiting NCT02318147 - Fecal Microbiota Transplantation for Pancreatitis With Infectious Complications(FMTPIC) Phase 1
Completed NCT02318134 - Fecal Microbiota Transplantation for Pancreatitis Phase 2
Active, not recruiting NCT04173208 - Main Trial of the Cesarean Section and Intestinal Flora of the Newborn Study N/A
Terminated NCT04577729 - The IRMI-FMT Trial N/A
Not yet recruiting NCT02435160 - The Study of Efficacy and Mechanism in Fecal Microbiota Transplantation in the Treatment of Ulcerative Colitis Phase 2/Phase 3
Recruiting NCT04837313 - Efficacy and Safety of Fecal Microbiota Transplantation in the Treatment of Parkinson's Disease With Constipation N/A
Recruiting NCT04861649 - Metabonomics of COPD and Transplanting of Faecal Bacteria in the Treatment of Its Malnutrition N/A
Withdrawn NCT04078581 - Profiling Fecal Samples for Selection of Donors of Feces N/A
Recruiting NCT05821010 - Synbiotics and Fecal Microbiota Transplantation to Treat Non-Alcoholic Steatohepatitis Phase 2
Recruiting NCT05273255 - Fecal Microbiota Transplantation in Patients With Malignancies Not Responding to Cancer Immunotherapy N/A
Not yet recruiting NCT05253222 - Methodology and Clinical Value of RIT in Intestinal Obstructive Diseases Mediated by Colonic TET N/A
Recruiting NCT04285424 - FMT for Steroid Resistant Gut Acute GVHD Early Phase 1
Withdrawn NCT03527056 - Pilot Study Using Oral Capsule FMT to Decolonize GI CRE Early Phase 1
Recruiting NCT03018613 - Fecal Microbiota Transplantation for Chronic Functional Constipation Phase 1/Phase 2